DK2572735T3 - Billeddannelses-diagnostik ved kombinering af kontrastmidler - Google Patents
Billeddannelses-diagnostik ved kombinering af kontrastmidler Download PDFInfo
- Publication number
- DK2572735T3 DK2572735T3 DK12199299T DK12199299T DK2572735T3 DK 2572735 T3 DK2572735 T3 DK 2572735T3 DK 12199299 T DK12199299 T DK 12199299T DK 12199299 T DK12199299 T DK 12199299T DK 2572735 T3 DK2572735 T3 DK 2572735T3
- Authority
- DK
- Denmark
- Prior art keywords
- eccm
- lscm
- imaging
- lesion
- 99mtc
- Prior art date
Links
- 239000002872 contrast media Substances 0.000 title claims description 107
- 238000002059 diagnostic imaging Methods 0.000 title description 3
- 230000003902 lesion Effects 0.000 claims description 78
- 238000003384 imaging method Methods 0.000 claims description 60
- 238000003745 diagnosis Methods 0.000 claims description 35
- IZOOGPBRAOKZFK-UHFFFAOYSA-K gadopentetate Chemical group [Gd+3].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O IZOOGPBRAOKZFK-UHFFFAOYSA-K 0.000 claims description 22
- 108010055917 Technetium Tc 99m Mertiatide Proteins 0.000 claims description 10
- 229960003638 dopamine Drugs 0.000 claims description 10
- 229960002700 octreotide Drugs 0.000 claims description 10
- 238000007500 overflow downdraw method Methods 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 claims 1
- 229960003473 androstanolone Drugs 0.000 claims 1
- 229940058213 medronate Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 43
- 206010028980 Neoplasm Diseases 0.000 description 25
- 230000008030 elimination Effects 0.000 description 21
- 238000003379 elimination reaction Methods 0.000 description 21
- 239000000126 substance Substances 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 201000010099 disease Diseases 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 238000002600 positron emission tomography Methods 0.000 description 8
- 230000011664 signaling Effects 0.000 description 8
- 229960003604 testosterone Drugs 0.000 description 7
- 230000004075 alteration Effects 0.000 description 6
- 230000004858 capillary barrier Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 206010015866 Extravasation Diseases 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000012879 PET imaging Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000036251 extravasation Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 238000002603 single-photon emission computed tomography Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000002586 coronary angiography Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000003748 differential diagnosis Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000005810 radionecrosis Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000005163 right hepatic lobe Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MKXBOPXRKXGSTI-PJKMHFRUSA-N 1-[(2s,4s,5r)-2-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@]1(F)O[C@H](CO)[C@@H](O)C1 MKXBOPXRKXGSTI-PJKMHFRUSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 239000002616 MRI contrast agent Substances 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testosterone Natural products O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 1
- 206010043903 Tobacco abuse Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940000032 cardiovascular system drug Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LGMLJQFQKXPRGA-VPVMAENOSA-K gadopentetate dimeglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O LGMLJQFQKXPRGA-VPVMAENOSA-K 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/481—Diagnostic techniques involving the use of contrast agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
- A61K49/105—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA the metal complex being Gd-DTPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Medical Informatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- High Energy & Nuclear Physics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (2)
1. Ekstracellulært kontrastmedium (ECCM) til anvendelse i diagnose af læsioner, hvor ECCM er gadolinium-DTPA (gadopentetinsyre/dimegluminsalt), hvor ECCM skal anvendes i kombination med et læsions-specifikt kontrastmedium (LSCM), og hvor LSCM er valgt fra gruppen omfattende 99mTc-Medronat, 99mTc-Sestamibi, 99mTc-ECD, 99mTc-MAG3, mln-DTPY-octreotid, mIn-DTPA-octreotat, 18F-fluor-desoxyglucose (FDG), 18F-dopamin, 18F-L-DOPA, 18F-fluorcholin, 18F-fluor-methylethylcholin, 18F-fluordihydro-testosteron, 68Ga-NODAGATOC, 68Ga-DOTYTOC, og hvor de individuelle kontrastmidler af kombinationen af ECCM og LSCM er billeddannelseskontrastmidler der skal anvendes i en multipel syntetisk billeddannelsesfremgangsmåde (polymodal), hvor den syntetiske billeddannelsesfremgangsmåde er en fusionsfremgangsmåde valgt fra gruppen omfattende PET-MRI og SPECT-MRT - og hvor enten a. ECCM og LSCM skal administreres efter hinanden; eller b. ECCM og LSCM skal administreres simultant, og hvor LSCM beriges i læsionen efter 10 minutter og opretholdes der i mindst 1 time, og hvor billeddannelsessignalerne umiddelbart interpoleres.
2. Ekstracellulært kontrastmedium (ECCM) til anvendelse i diagnose af læsion der skal anvendes i kombination med et læsions-specifikt kontrastmedium (LSCM) ifølge krav 1, hvor ECCM og LSCM skal administreres med en tidsforskydning på mindst 10 til 15 minutter.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07110922A EP2005970A1 (de) | 2007-06-22 | 2007-06-22 | Bildgebende Diagnostik durch Kombination von Kontrastmitteln |
| EP12168380A EP2514442A3 (en) | 2007-06-22 | 2008-06-20 | Imaging diagnostics by combining contrast agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2572735T3 true DK2572735T3 (da) | 2015-03-30 |
Family
ID=38627016
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08774183.1T DK2170405T3 (da) | 2007-06-22 | 2008-06-20 | Billedvisningsdiagnostik ved kombination af kontrastmidler |
| DK12199299T DK2572735T3 (da) | 2007-06-22 | 2008-06-20 | Billeddannelses-diagnostik ved kombinering af kontrastmidler |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08774183.1T DK2170405T3 (da) | 2007-06-22 | 2008-06-20 | Billedvisningsdiagnostik ved kombination af kontrastmidler |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20110243847A1 (da) |
| EP (6) | EP2005970A1 (da) |
| CY (1) | CY1116213T1 (da) |
| DK (2) | DK2170405T3 (da) |
| ES (2) | ES2534970T3 (da) |
| HR (1) | HRP20150472T1 (da) |
| PL (2) | PL2572735T3 (da) |
| PT (1) | PT2572735E (da) |
| SI (2) | SI2572735T1 (da) |
| WO (1) | WO2009000777A2 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10032268B2 (en) | 2012-08-06 | 2018-07-24 | Koninklijke Philips N.V. | Dynamic contrast-enhanced imaging based permeability metric |
| RU2706373C1 (ru) * | 2019-03-01 | 2019-11-18 | Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации | Способ определения локализации опухолевой обструкции билиарного тракта и степени её распространенности |
| US11730831B2 (en) | 2019-03-26 | 2023-08-22 | Sicreations, Llc | Imaging agents and methods of using the same |
| EP3976117A4 (en) | 2019-05-29 | 2023-02-01 | Sicreations, LLC | METHODS OF CONSERVING A SUBJECT AND USING IMAGING CONTRAST AGENTS |
| US11300695B2 (en) | 2020-04-24 | 2022-04-12 | Ronald Nutt | Time-resolved positron emission tomography encoder system for producing event-by-event, real-time, high resolution, three-dimensional positron emission tomographic image without the necessity of performing image reconstruction |
| US11054534B1 (en) | 2020-04-24 | 2021-07-06 | Ronald Nutt | Time-resolved positron emission tomography encoder system for producing real-time, high resolution, three dimensional positron emission tomographic image without the necessity of performing image reconstruction |
| CN115785468A (zh) * | 2022-11-21 | 2023-03-14 | 苏州大学 | 一种用于富集细胞外囊泡的zif-8-dspe材料及其制备方法和应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4647447A (en) | 1981-07-24 | 1987-03-03 | Schering Aktiengesellschaft | Diagnostic media |
| US4444690A (en) | 1982-02-25 | 1984-04-24 | University Patents, Inc. | Technetium chelates |
| US4673562A (en) | 1983-08-19 | 1987-06-16 | The Children's Medical Center Corporation | Bisamide bisthiol compounds useful for making technetium radiodiagnostic renal agents |
| US4670545A (en) | 1984-05-11 | 1987-06-02 | University Patents, Inc. | Chelating agents for technetium-99M |
| US4980147A (en) | 1984-06-25 | 1990-12-25 | University Of Utah Research Foundation | Radiolabeled technetium chelates for use in renal function determinations |
| US4897255A (en) | 1985-01-14 | 1990-01-30 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
| US4965392A (en) | 1987-03-26 | 1990-10-23 | Neorx Corporation | Chelating compounds for metal-radionuclide labeled proteins |
| ES2033433T3 (es) | 1987-07-16 | 1993-03-16 | Nycomed As | Procedimiento para preparar acidos aminopolicarboxilicos y sus derivados. |
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| GB8808305D0 (en) | 1988-04-08 | 1988-05-11 | Nycomed As | Compositions |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US4988496A (en) | 1988-05-31 | 1991-01-29 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5059415A (en) * | 1989-02-21 | 1991-10-22 | The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon Health | Method for diagnostically imaging lesions in the brain inside a blood-brain barrier |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| US5078985A (en) | 1989-08-09 | 1992-01-07 | Rhomed, Incorporated | Radiolabeling antibodies and other proteins with technetium or rhenium by regulated reduction |
| JPH03228046A (ja) | 1989-09-13 | 1991-10-09 | Konica Corp | 赤外吸収染料を有し経時安定性に優れる写真材料 |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| KR950703582A (ko) | 1992-10-14 | 1995-09-20 | 조이스 이. 마임스 | 킬레이트화 중합체(chelating polymers) |
| ES2140469T3 (es) | 1992-10-14 | 2000-03-01 | Nycomed Imaging As | Composiciones y metodos terapeuticos y de diagnostico por obtencion de imagenes. |
| US5756688A (en) | 1992-10-14 | 1998-05-26 | Sterling Winthrop Inc. | MR imaging compositions and methods |
| AU5733994A (en) | 1992-11-30 | 1994-06-22 | Wellcome Foundation Limited, The | Sequential targeting of tumor sites with oligonucleotide conjugates of antibody and complementary oligonucleotide conjugates of chelated radionuclide |
| WO1994013327A1 (en) | 1992-12-15 | 1994-06-23 | The Wellcome Foundation Limited | Immunoreactive reagents employing dihydrofolate reductase |
| US5559214A (en) | 1993-05-28 | 1996-09-24 | Sterling Winthrop Inc. | Unsymmetrical complexing agents and targeting immunoreagents useful in thearpeutic and diagnostic compositions and methods |
| AU7244894A (en) | 1993-06-07 | 1995-01-03 | Wellcome Foundation Limited, The | Immunoreactive reagents employing monoamine oxidase |
| DE4326466A1 (de) | 1993-08-06 | 1995-02-09 | Boehringer Mannheim Gmbh | Infrarot-Farbstoff-markierte Nucleotide und ihre Verwendung in der Nucleinsäure-Detektion |
| US5730968A (en) | 1994-03-31 | 1998-03-24 | Sterling Winthrop Inc. | Segmented chelating polymers as imaging and therapeutic agents |
| DE4445065A1 (de) | 1994-12-07 | 1996-06-13 | Diagnostikforschung Inst | Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung |
| US5591217A (en) | 1995-01-04 | 1997-01-07 | Plexus, Inc. | Implantable stimulator with replenishable, high value capacitive power source and method therefor |
| ATE264694T1 (de) | 1995-01-30 | 2004-05-15 | Daiichi Pure Chemicals Co Ltd | Diagnostisches markierungsmittel |
| KR100500334B1 (ko) | 1996-02-19 | 2005-09-09 | 아머샴 헬스 에이에스 | 조영제또는그와관련된개선 |
| US6490476B1 (en) * | 1999-10-14 | 2002-12-03 | Cti Pet Systems, Inc. | Combined PET and X-ray CT tomograph and method for using same |
| US6628982B1 (en) | 2000-03-30 | 2003-09-30 | The Regents Of The University Of Michigan | Internal marker device for identification of biological substances |
| WO2001082864A2 (en) * | 2000-04-28 | 2001-11-08 | Duke University | 18f-labeled choline analogs |
| AU2002239655A1 (en) * | 2001-01-05 | 2002-07-16 | Duke University | Contrast enhancement agent for magnetic resonance imaging |
| US7286867B2 (en) | 2003-10-16 | 2007-10-23 | Brookhaven Science Associates, Llc | Combined PET/MRI scanner |
| WO2007008232A2 (en) * | 2004-09-03 | 2007-01-18 | Board Of Regents, The University Of Texas System | Locoregional internal radionuclide ablation of abnormal tissues. |
| GB0422004D0 (en) | 2004-10-05 | 2004-11-03 | Amersham Plc | Method of deprotection |
| EP2990073B1 (en) | 2004-11-24 | 2018-05-02 | Bayer Healthcare LLC | Devices and systems for fluid delivery |
| EP1853161A4 (en) | 2004-12-29 | 2011-03-23 | Siemens Medical Solutions | COMBINED PET / MR SYSTEM AND APD-BASED PET DETECTOR FOR USE IN SIMULTANEOUS PET / MR PRESENTATION |
| US7670315B2 (en) | 2005-01-21 | 2010-03-02 | Medrad, Inc. | Injectors, injector systems and methods for injecting fluids |
| CN101175517A (zh) | 2005-05-16 | 2008-05-07 | 马林克罗特公司 | 具有一体化管路的多筒注射器 |
| DE102005023906B4 (de) | 2005-05-24 | 2013-01-31 | Siemens Aktiengesellschaft | Verfahren zur Ermittlung von Positronen-Emissions-Messinformationen im Rahmen der Positronen-Emissions-Tomographie |
| DE102005040107B3 (de) | 2005-08-24 | 2007-05-31 | Siemens Ag | Kombiniertes PET-MRT-Gerät und Verfahren zur gleichzeitigen Aufnahme von PET-Bildern und MR-Bildern |
| DE102005045600B4 (de) | 2005-09-23 | 2008-01-17 | Siemens Ag | Injektor und Verfahren zum Unterstützen der Bildgebung an einem Patienten |
| US20080008366A1 (en) * | 2006-06-20 | 2008-01-10 | Vladimir Desh | Simultaneous visualization, analysis and navigation of multi-modality medical imaging data |
| US20080146914A1 (en) * | 2006-12-19 | 2008-06-19 | General Electric Company | System, method and apparatus for cancer imaging |
-
2007
- 2007-06-22 EP EP07110922A patent/EP2005970A1/de not_active Withdrawn
-
2008
- 2008-06-20 EP EP12168380A patent/EP2514442A3/en not_active Withdrawn
- 2008-06-20 PL PL12199299T patent/PL2572735T3/pl unknown
- 2008-06-20 SI SI200831412T patent/SI2572735T1/sl unknown
- 2008-06-20 ES ES12199299.4T patent/ES2534970T3/es active Active
- 2008-06-20 PT PT121992994T patent/PT2572735E/pt unknown
- 2008-06-20 WO PCT/EP2008/057886 patent/WO2009000777A2/en active Application Filing
- 2008-06-20 PL PL08774183T patent/PL2170405T3/pl unknown
- 2008-06-20 US US12/666,205 patent/US20110243847A1/en not_active Abandoned
- 2008-06-20 EP EP12199299.4A patent/EP2572735B1/en active Active
- 2008-06-20 ES ES08774183T patent/ES2395436T3/es active Active
- 2008-06-20 EP EP08774183A patent/EP2170405B1/en not_active Revoked
- 2008-06-20 DK DK08774183.1T patent/DK2170405T3/da active
- 2008-06-20 DK DK12199299T patent/DK2572735T3/da active
- 2008-06-20 EP EP15155866.5A patent/EP2907526A1/en not_active Withdrawn
- 2008-06-20 EP EP13174573.9A patent/EP2647392A3/en not_active Withdrawn
- 2008-06-20 SI SI200830844T patent/SI2170405T1/sl unknown
-
2013
- 2013-04-11 US US13/860,675 patent/US9179882B2/en active Active
-
2015
- 2015-04-22 CY CY20151100372T patent/CY1116213T1/el unknown
- 2015-05-04 HR HRP20150472TT patent/HRP20150472T1/hr unknown
- 2015-09-21 US US14/859,595 patent/US9682159B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SI2170405T1 (sl) | 2013-01-31 |
| US20160008496A1 (en) | 2016-01-14 |
| PL2572735T3 (pl) | 2015-07-31 |
| EP2647392A3 (en) | 2014-01-08 |
| EP2647392A2 (en) | 2013-10-09 |
| ES2395436T3 (es) | 2013-02-12 |
| CY1116213T1 (el) | 2017-03-15 |
| US9682159B2 (en) | 2017-06-20 |
| WO2009000777A4 (en) | 2009-10-01 |
| EP2170405B1 (en) | 2012-09-12 |
| EP2572735B1 (en) | 2015-02-25 |
| US20110243847A1 (en) | 2011-10-06 |
| EP2907526A1 (en) | 2015-08-19 |
| EP2572735A1 (en) | 2013-03-27 |
| PL2170405T3 (pl) | 2013-06-28 |
| US9179882B2 (en) | 2015-11-10 |
| WO2009000777A3 (en) | 2009-08-13 |
| EP2514442A3 (en) | 2013-03-20 |
| SI2572735T1 (sl) | 2015-05-29 |
| EP2005970A1 (de) | 2008-12-24 |
| EP2514442A2 (en) | 2012-10-24 |
| WO2009000777A2 (en) | 2008-12-31 |
| US20130224113A1 (en) | 2013-08-29 |
| DK2170405T3 (da) | 2013-01-07 |
| ES2534970T3 (es) | 2015-04-30 |
| EP2170405A2 (en) | 2010-04-07 |
| HRP20150472T1 (en) | 2015-06-05 |
| PT2572735E (pt) | 2015-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Daghini et al. | Assessment of renal hemodynamics and function in pigs with 64-section multidetector CT: comparison with electron-beam CT | |
| Qanadli et al. | Helical CT phlebography of the superior vena cava: diagnosis and evaluation of venous obstruction. | |
| Oda et al. | Low contrast and radiation dose coronary CT angiography using a 320-row system and a refined contrast injection and timing method | |
| DK2572735T3 (da) | Billeddannelses-diagnostik ved kombinering af kontrastmidler | |
| Stewart et al. | Correlation between hepatic tumor blood flow and glucose utilization in a rabbit liver tumor model | |
| Daghini et al. | Comparison of mathematic models for assessment of glomerular filtration rate with electron-beam CT in pigs | |
| Alameen et al. | Radiobiological risks in terms of effective dose and organ dose from 18F-FDG whole-body PET/CT procedures | |
| US10201321B2 (en) | Low-dose CT perfusion technique | |
| Liu et al. | Renal perfusion and hemodynamics: accurate in vivo determination at CT with a 10-fold decrease in radiation dose and HYPR noise reduction | |
| Kahn | Renal imaging with radionuclides, ultrasound, and computed tomography | |
| Chen et al. | Scope of diagnostic imaging | |
| Du et al. | The clinical application of 320-detector row CT in transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma | |
| van Leeuwen et al. | Potential value of color-coded dynamic breast-specific gamma-imaging; comparing 99mTc-(V)-DMSA, 99mTc-MIBI, and 99mTc-HDP in a mouse mammary tumor model | |
| Schütz | The potential of magnetic particle imaging in the competitive environment of cardiac diagnostics | |
| Tateishi et al. | A comparison between injection speed and iodine delivery rate in contrast-enhanced computed tomography (CT) for normal beagles | |
| US20200330618A1 (en) | Preparation for magnetic resonance diagnostics for oncological diseases, comprising deuterated 3-o-methylglucose, and diagnostic method using said preparation | |
| Henes et al. | Intraindividual comparison of gadolinium-and iodine-enhanced 64-slice multidetector CT pulmonary angiography for the detection of pulmonary embolism in a porcine model | |
| RU2156112C1 (ru) | Способ определения васкуляризации очаговых поражений печени | |
| RU2190959C2 (ru) | Способ диагностики очаговых поражений селезенки | |
| RU2772636C1 (ru) | Способ обследования пациентов с подозрением на воспаление в стенке аневризматически расширенной восходящей аорты | |
| RU2786824C1 (ru) | Способ оценки степени злокачественности опухолей головного мозга | |
| Jacquier et al. | MDCT of the myocardium: a new contribution to ischemic heart disease | |
| Otsuka | Clinical imaging technology and the diagnosis in patient-centered interdisciplinary care | |
| Izquierdo-Garcia et al. | Dosimetry of [64Cu] FBP8: a fibrin-binding PET probe | |
| Yang et al. | Cone beam CT tumor vasculature dynamic study (Murine model) |